APO-MOXIFLOXACIN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
31-08-2020
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
から入手可能:
APOTEX INC
ATCコード:
J01MA14
INN（国際名）:
MOXIFLOXACIN
投薬量:
400MG
医薬品形態:
TABLET
構図:
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
治療領域:
QUINOLONES
製品概要:
Active ingredient group (AIG) number: 0142242001; AHFS:
認証ステータス:
APPROVED
承認日:
2016-01-07
製品の特徴
Page 1 of 66
PRODUCT MONOGRAPH
PR
APO-MOXIFLOXACIN
Moxifloxacin Tablets
400 mg Moxifloxacin (as moxifloxacin hydrochloride)
House Standard
Antibacterial Agent
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
CANADA
Date of Revision:
August 31, 2020
SUBMISSION CONTROL NO: 240946
Page 2 of 66
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
6
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
.........................................................................................................
18
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
22
STORAGE AND STABILITY
.................................................................................................
29
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 29
PART II: SCIENTIFIC INFORMATION .......................................................................................
31
PHARMACEUTICAL INFORMATION
.................................................................
完全なドキュメントを読む
